FLT3 Inhibitors: A paradigm for the development of targeted therapeutics for paediatric cancer

European Journal of Cancer

Volumn 40, Issue 5, 2004, Pages 707-721

  Brown, P ^a   Small, D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; BCR ABL PROTEIN; CARBAZOLE DERIVATIVE; CEP 701; DEPSIPEPTIDE; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMATINIB; INDOLINONE; MIDOSTAURIN; MONOCLONAL ANTIBODY; MYELOTARG; OBLIMERSEN; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RETINOIC ACID; RITUXIMAB; SEMAXANIB; STAUROSPORINE; SUNITINIB; TIPIFARNIB; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN PRESENTING CELL; BIOLOGICAL MODEL; CANCER CELL CULTURE; CANCER CENTER; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG TARGETING; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MYELODYSPLASTIC SYNDROME; ONCOLOGY; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TISSUE EXPANSION; VALIDATION PROCESS;

EID: 1542269168     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.08.030     Document Type: Article

References (138)

1. Druker B.J. Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. 40:2003;50-58.
2. Children's Oncology Group Website. In: Children's Oncology Group; 2003.
3. National Cancer Institute Clinical Trials Website. In: National Cancer Institute; 2003.
4. Tallman M.S., Andersen J.W., Schiffer C.A.et al. All-trans retinoic acid in acute promyelocytic leukemia. long-term outcome and prognostic factor analysis from the North American Intergroup protocol Blood. 100:2002;4298-4302.
5. Reynolds C.P., Lemons R.S. Retinoid therapy of childhood cancer. Hematol. Oncol. Clin. North. Am. 15:2001;867-910.
6. Kushner B.H., Kramer K., Cheung N.K. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J. Clin. Oncol. 19:2001;4189-4194.
7. Cohen M.H., Williams G., Johnson J.R.et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8:2002;935-942.
8. Druker B.J., Talpaz M., Resta D.J.et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037.
9. van Oosterom A.T., Judson I., Verweij J.et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours. a phase I study Lancet. 358:2001;1421-1423.
10. Dagher R., Cohen M., Williams G.et al. Approval summary. imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors Clin. Cancer Res. 8:2002;3034-3038.
11. Slamon D.J., Leyland-Jones B., Shak S.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
12. Vogel C.L., Cobleigh M.A., Tripathy D.et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:2002;719-726.
13. Cobleigh M.A., Vogel C.L., Tripathy D.et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:1999;2639-2648.
14. Baselga J., Rischin D., Ranson M.et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:2002;4292-4302.
15. Herbst R.S., Maddox A.M., Rothenberg M.L.et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors. results of a phase I trial J. Clin. Oncol. 20:2002;3815-3825.
16. Ranson M., Hammond L.A., Ferry D.et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors. results of a phase I trial J. Clin. Oncol. 20:2002;2240-2250.
17. Hainsworth J.D., Litchy S., Burris 3rd H.A.et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J. Clin. Oncol. 20:2002;4261-4267.
18. McLaughlin P., Grillo-Lopez A.J., Link B.K.et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma. half of patients respond to a four-dose treatment program J. Clin. Oncol. 16:1998;2825-2833.
19. Davis T.A., Grillo-Lopez A.J., White C.A.et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma. safety and efficacy of re-treatment J. Clin. Oncol. 18:2000;3135-3143.
20. Sievers E.L., Larson R.A., Stadtmauer E.A.et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19:2001;3244-3254.
21. Bross P.F., Beitz J., Chen G.et al. Approval summary. gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin. Cancer Res. 7:2001;1490-1496.
22. Merchant M.S., Woo C.W., Mackall C.L., Thiele C.J. Potential use of imatinib in Ewing's Sarcoma. evidence for in vitro and in vivo activity J. Natl. Cancer Inst. 94:2002;1673-1679.
23. Smithey B.E., Pappo A.S., Hill D.A. C-kit expression in pediatric solid tumors. a comparative immunohistochemical study Am. J. Surg. Pathol. 26:2002;486-492.
24. Singer S., Rubin B.P., Lux M.L.et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 20:2002;3898-3905.
25. Morey A.L., Wanigesekera G.D., Hawkins N.J., Ward R.L. C-kit mutations in gastrointestinal stromal tumours. Pathology. 34:2002;315-319.
26. Akatsuka T., Wada T., Kokai Y., Sawada N., Yamawaki S., Ishii S. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology. 60:2001;361-366.
27. Gorlick R., Huvos A.G., Heller G.et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 17:1999;2781-2788.
28. Kilpatrick S.E., Geisinger K.R., King T.S.et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod. Pathol. 14:2001;1277-1283.
29. Onda M., Matsuda S., Higaki S.et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 77:1996;71-78.
30. Zhou H., Randall R.L., Brothman A.R., Maxwell T., Coffin C.M., Goldsby R.E. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J. Pediatr. Hematol. Oncol. 25:2003;27-32.
31. Lyman S.D. Biology of flt3 ligand and receptor. Int. J. Hematol. 62:1995;63-73.
32. Small D., Levenstein M., Kim E.et al. STK-1, the human homolog of Flk2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proceedings of the National Academy of Sciences, USA. 91:1994;459-463.
33. Rosnet O., Schiff C., Pebusque M.-J.et al. Human FLT3/FLK2 gene. CDNA cloning and expression in hematopoietic cells Blood. 82:1993;1110-1119.
34. Gotze K.S., Ramirez M., Tabor K., Small D., Matthews W., Civin C.I. Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood. 91:1998;1947-1958.
35. McKenna H.J. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr. Opin. Hematol. 8:2001;149-154.
36. Mackarehtschian K., Hardin J.D., Moore K.A., Boast S., Goff S.P., Lemischka I.R. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 3:1995;147-161.
37. McKenna H.J., Stocking K.L., Miller R.E.et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 95:2000;3489-3497.
38. Maroc N., Rottapel R., Rosnet O.et al. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene. 8:1993;909-918.
39. deLapeyriere O., Naquet P., Planche J.et al. Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues. Differentiation. 58:1995;351-359.
40. Lisovsky M., Braun S.E., Ge Y.et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia. 10:1996;1012-1018.
41. Lyman S.D., James L., Vanden Bos T.et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor. a proliferative factor for primitive hematopoietic cells Cell. 75:1993;1157-1167.
42. Lyman S.D., James L., Johnson L.et al. Cloning of the human homologue of the murine flt3 ligand. a growth factor for early hematopoietic progenitor cells Blood. 83:1994;2795-2801.
43. Lavagna-Sevenier C., Marchetto S., Birnbaum D., Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia. 12:1998;301-310.
44. Zhang S., Broxmeyer H.E. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem. Biophys. Res. Commun. 277:2000;195-199.
45. Zhang S., Mantel C., Broxmeyer H.E. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J. Leukoc. Biol. 65:1999;372-380.
46. Zhang S., Broxmeyer H.E. p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine- phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Biochem. Biophys. Res. Commun. 254:1999;440-445.
47. Rosnet O., Buhring H.J., deLapeyriere O.et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. 95:1996;218-223.
48. Zhang S., Fukuda S., Lee Y.et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J. Exp. Med. 192:2000;719-728.
49. Carow C.E., Levenstein M., Kaufmann S.H.et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 87:1996;1089-1096.
50. Rosnet O., Buhring H.J., Marchetto S.et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 10:1996;238-248.
51. Birg F., Courcoul M., Rosnet O.et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood. 80:1992;2584-2593.
52. Meierhoff G., Dehmel U., Gruss H.J.et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. 9:1995;1368-1372.
53. Drexler H.G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 10:1996;588-599.
54. Zheng R., Levis M., Pilato O.et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cell. Blood. 103(1):2004;267-274.
55. Armstrong S.A., Staunton J.E., Silverman L.B.et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30:2002;41-47.
56. Armstrong S.A., Kung A.L., Mabon M.E.et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 3:2003;173-183.
57. Nakao M., Yokota S., Iwai T.et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 10:1996;1911-1918.
58. Kiyoi H., Towatari M., Yokota S.et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 12:1998;1333-1337.
59. Kiyoi H., Ohno R., Ueda R., Saito H., Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 21:2002;2555-2563.
60. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 100:2002;1532-1542.
61. Yamamoto Y., Kiyoi H., Nakano Y.et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97:2001;2434-2439.
62. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R., Reilly J.T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 113:2001;983-988.
63. Thiede C., Steudel C., Mohr B.et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia. association with FAB subtypes and identification of subgroups with poor prognosis Blood. 99:2002;4326-4335.
64. Spiekermann K., Bagrintseva K., Schoch C., Haferlach T., Hiddemann W., Schnittger S. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood. 100:2002;3423-3425.
65. Binns K.L., Taylor P.P., Sicheri F., Pawson T., Holland S.J. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol. Cell. Biol. 20:2000;4791-4805.
66. Favelyukis S., Till J.H., Hubbard S.R., Miller W.T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol. 8:2001;1058-1063.
67. Mohammadi M., Dikic I., Sorokin A., Burgess W.H., Jaye M., Schlessinger J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell. Biol. 16:1996;977-989.
68. Wybenga-Groot L.E., Baskin B., Ong S.H., Tong J., Pawson T., Sicheri F. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell. 106:2001;745-757.
69. Yokota S., Kiyoi H., Nakao M.et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 11:1997;1605-1609.
70. Stirewalt D.L., Kopecky K.J., Meshinchi S.et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 97:2001;3589-3595.
71. Kiyoi H., Naoe T., Nakan Y.et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 93:1999;3074-3080.
72. Rombouts W.J., Blokland I., Lowenberg B., Ploemacher R.E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 14:2000;675-683.
73. Abu-Duhier F.M., Goodeve A.C., Wilson G.A.et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. 111:2000;190-195.
74. Kottaridis P.D., Gale R.E., Frew M.E.et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy. analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood. 98:2001;1752-1759.
75. Whitman S.P., Archer K.J., Feng L.et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3. a cancer and leukemia group B study Cancer Res. 61:2001;7233-7239.
76. Frohling S., Schlenk R.F., Breitruck J.et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics. a study of the AML Study Group Ulm Blood. 100:2002;4372-4380.
77. Boissel N., Cayuela J.M., Preudhomme C.et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. 16:2002;1699-1704.
78. Schnittger S., Schoch C., Dugas M.et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia. correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood. 100:2002;59-66.
79. Moreno I., Martin G., Bolufer P.et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 88:2003;19-24.
80. Horiike S., Yokota S., Nakao M.et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 11:1997;1442-1446.
81. Arrigoni P., Beretta C., Silvestri D.et al. FLT3 internal tandem duplication in childhood acute myeloid leukaemia. association with hyperleucocytosis in acute promyelocytic leukaemia Br. J. Haematol. 120:2003;89-92.
82. Liang D.C., Shih L.Y., Hung I.J.et al. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer. 94:2002;3292-3298.
83. Meshinchi S., Woods W.G., Stirewalt D.L.et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 97:2001;89-94.
84. Xu F., Taki T., Yang H.W.et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. 105:1999;155-162.
85. Kondo M., Horibe K., Takahashi Y.et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med. Pediatr. Oncol. 33:1999;525-529.
86. Iwai T., Yokota S., Nakao M.et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia. 13:1999;38-43.
87. Nakao M., Janssen J.W., Erz D., Seriu T., Bartram C.R. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia. a marker for the monitoring of minimal residual disease Leukemia. 14:2000;522-524.
88. Baldwin B.R.et al. FLT3 is not frequently mutated in solid tumors [abstract]. Blood. 98:2001;156b.
89. Meshinchi S., Stirewalt D.L., Alonzo T.A.et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 102:2003;1474-1479.
90. Levis M., Allebach J., Tse K.F.et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 99:2002;3885-3891.
91. Mizuki M., Fenski R., Halfter H.et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 96:2000;3907-3914.
92. Tse K.F., Mukherjee G., Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 14:2000;1766-1776.
93. Baldwin B.R.et al. Transgenic mice expressing a constitutively activated FLT3 receptor display a myeloproliferative disease phenotype [abstract]. Blood. 98:2001;801a.
94. Kelly L.M., Liu Q., Kutok J.L., Williams I.R., Boulton C.L., Gilliland D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 99:2002;310-318.
95. Kelly L.M., Kutok J.L., Williams I.R.et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8283-8288.
96. Minami Y., Kiyoi H., Yamamoto Y.et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia. 16:2002;1535-1540.
97. Hayakawa F., Towatari M., Kiyoi H.et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 19:2000;624-631.
98. Tse K.F., Allebach J., Levis M., Smith B.D., Bohmer F.D., Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia. 16:2002;2027-2036.
99. Zhang S., Fukuda S., Lee Y.et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J. Exp. Med. 192:2000;719-728.
100. Quentmeier H., Reinhardt J., Zaborski M., Drexler H.G. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 17:2003;120-124.
101. Mizuki M., Schwable J., Steur C.et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 101:2003;3164-3173.
102. Kim K.et al. Pim-1 and Myc expressions are remarkably decreased in response to FLT3 inhibitor in FLT3-expressing leukemia cells [abstract]. Blood. 100:2002;138a.
103. van Lohuizen M., Verbeek S., Krimpenfort P.et al. Predisposition to lymphomagenesis in pim-1 transgenic mice. cooperation with c-myc and N-myc in murine leukemia virus-induced tumors Cell. 56:1989;673-682.
104. Breuer M.L., Cuypers H.T., Berns A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. Embo J. 8:1989;743-748.
105. Allen J.D., Verhoeven E., Domen J., van der Valk M., Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 15:1997;1133-1141.
106. Nieborowska-Skorska M., Hoser G., Kossev P., Wasik M.A., Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood. 99:2002;4531-4539.
107. Acton D., Domen J., Jacobs H., Vlaar M., Korsmeyer S., Berns A. Collaboration of pim-1 and bcl-2 in lymphomagenesis. Curr. Top. Microbiol. Immunol. 182:1992;293-298.
108. Zheng R. Regulation of STAT3 and STAT5 in the differentiation of FLT3/ ITD expressing 32Dcl3 cells induced by G-CSF and CEP-701 [abstract]. Blood. 98:2002;742a.
109. Zheng R., Friedman A.D., Small D. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood. 100:2002;4154-4161.
110. Chen P.et al. Expression of FLT3/ITD mutations suppresses SHP-1 [abstract]. Blood. 100:2002;85a.
111. Weisberg E., Boulton C., Kelly L.M.et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443.
112. Spiekermann K., Dirschinger R.J., Schwab R.et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 101:2003;1494-1504.
113. Hawley T.S., Fong A.Z., Griesser H., Lyman S.D., Hawley R.G. Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. Blood. 92:1998;2003-2011.
114. Tse K.F., Novelli E., Civin C.I., Bohmer F.D., Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 15:2001;1001-1010.
115. Levis M., Tse K.F., Smith B.D., Garrett E., Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 98:2001;885-887.
116. George D.J., Dionne C.A., Jani J.et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. 59:1999;2395-2401.
117. Smith B.D., Levis M., Beram M.et al. Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical in patients with refractory acute myeloid leukemia. Blood. 2004;in press.
118. Stone R.M.et al. PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML). a phase II clinical trial [abstract] Blood. 100:2002;86a.
119. Yee K.W., O'Farrell A.M., Smolich B.D.et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 100:2002;2941-2949.
120. Giles F.J., Stopeck A.T., Silverman L.R.et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 102(3):2003;795-801.
121. O'Farrell A.M., Abrams T.J., Yuen H.A.et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101(9):2003;3597-3605.
122. Foran J.et al. A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for, conventional chemotherapy [abstract]. Blood. 100:2002;558a-559a.
123. O'Farrell A.M., Foran J., Fiedler W.et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 9(15):2003;5465-5476.
124. Kelly L.M., Yu J.C., Boulton C.L.et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1:2002;421-432.
125. Heinrich M.C.et al. A "first in man" study of the safety and PK/PD of an oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodysplasia [abstract]. Blood. 100:2002;336a-337a.
126. Zhao M., Kiyoi H., Yamamoto Y.et al. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia. 14:2000;374-378.
127. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 11:2000;355-360.
128. Shiotsu Y., Neckers L.M., Wortman I.et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood. 96:2000;2284-2291.
129. Rutherford S.L., Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature. 396:1998;336-342.
130. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3:1997;730-737.
131. Sirard C., Lapidot T., Vormoore J.et al. Normal and leukemic SCID-repopulating cells (SRC) co-exist in the bone marrow and peripheral blood from CML patients in chronic phase while leukemic SRC are detected in blast crisis. Blood. 87:1996;1539-1548.
132. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature. 414:2001;105-111.
133. Lumkul R., Gorin N.C., Malehorn M.T.et al. Human AML cells in NOD/SCID mice. engraftment potential and gene expression Leukemia. 16:2002;1818-1826.
134. Nakano Y., Kiyoi H., Miyawaki S.et al. Molecular evolution of acute myeloid leukaemia in relapse. unstable N-ras and FLT3 genes compared with p53 gene Br. J. Haematol. 104:1999;659-664.
135. Kottaridis P.D., Gale R.E., Langabeer S.E., Frew M.E., Bowen D.T., Linch D.C. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia. implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors Blood. 100:2002;2393-2398.
136. Zheng R., Friedman A.D., Levis M.et al. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression. Blood. 2003;in press.
137. Armstrong S.A., Mabon M.E., Silverman L.B., Li A., Gribben J.G., Fox E.A.et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;in press.
138. Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 103(3):2004;1085-1088.